Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Tazemetostat Plus Mosunetuzumab in Untreated Follicular Lymphoma

NCT05994235 is registered in ClinicalTrials.gov with Weill Medical College of Cornell University as lead sponsor.

NCT NCT05994235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05994235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Tazemetostat Plus Mosunetuzumab in Untreated Follicular Lymphoma
Lead sponsor
Weill Medical College of Cornell University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 1, 2023
Completion date
October 31, 2033
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma